- Home
- APLM vs AMPG Comparison
APLM vs AMPG Comparison
Compare APLM & AMPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- AMPG
- Stock Information
- Founded
- APLM 2016
- AMPG 2002
- Country
- APLM United States
- AMPG United States
- Employees
- APLM N/A
- AMPG N/A
- Industry
- APLM Blank Checks
- AMPG Telecommunications Equipment
- Sector
- APLM Finance
- AMPG Telecommunications
- Exchange
- APLM Nasdaq
- AMPG Nasdaq
- Market Cap
- APLM 12.3M
- AMPG 11.8M
- IPO Year
- APLM N/A
- AMPG N/A
- Fundamental
- Price
- APLM $7.02
- AMPG $1.85
- Analyst Decision
- APLM Strong Buy
- AMPG Strong Buy
- Analyst Count
- APLM 2
- AMPG 1
- Target Price
- APLM $425.00
- AMPG $5.00
- AVG Volume (30 Days)
- APLM 7.4K
- AMPG 810.9K
- Earning Date
- APLM 03-04-2025
- AMPG 03-31-2025
- Dividend Yield
- APLM N/A
- AMPG N/A
- EPS Growth
- APLM N/A
- AMPG N/A
- EPS
- APLM N/A
- AMPG N/A
- Revenue
- APLM $2,101,000.00
- AMPG $11,667,163.00
- Revenue This Year
- APLM N/A
- AMPG N/A
- Revenue Next Year
- APLM N/A
- AMPG $58.88
- P/E Ratio
- APLM N/A
- AMPG N/A
- Revenue Growth
- APLM 70.54
- AMPG N/A
- 52 Week Low
- APLM $6.38
- AMPG $0.64
- 52 Week High
- APLM $80.50
- AMPG $6.43
- Technical
- Relative Strength Index (RSI)
- APLM 37.88
- AMPG 41.86
- Support Level
- APLM $6.70
- AMPG $1.76
- Resistance Level
- APLM $7.60
- AMPG $2.09
- Average True Range (ATR)
- APLM 0.70
- AMPG 0.19
- MACD
- APLM -0.03
- AMPG -0.01
- Stochastic Oscillator
- APLM 22.30
- AMPG 11.11
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About AMPG Amplitech Group Inc.
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.